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Abstract 
 
Objective: Grey matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We 
investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with 
faster disability accumulation in MS. 
Methods: We analysed 3,604 brain high-resolution T1-weighted MRI scans from 1,417 
participants: 1,214 MS patients (253 clinically-isolated syndrome[CIS], 708 relapsing-
remitting[RRMS], 128 secondary-progressive[SPMS], 125 primary-progressive[PPMS]), 
over an average follow-up of 2.41 years (standard deviation[SD]=1.97), and 203 healthy 
controls (HCs) [average follow-up=1.83 year, SD=1.77], attending 7 European centres. 
Disability was assessed with the Expanded-Disability Status Scale (EDSS). We obtained 
volumes of the deep GM (DGM), temporal, frontal, parietal, occipital and cerebellar GM, 
brainstem and cerebral white matter. Hierarchical mixed-models assessed annual percentage 
rate of regional tissue loss and identified regional volumes associated with time-to-EDSS 
progression.  
Results: SPMS showed the lowest baseline volumes of cortical GM and DGM. Of all 
baseline regional volumes, only that of the DGM predicted time-to-EDSS progression 
(hazard ratio=0.73, 95% CIs 0.65, 0.82; p<0.001): for every standard deviation decrease in 
baseline DGM volume, the risk of presenting a shorter time to EDSS worsening during 
follow-up increased by 27%. Of all longitudinal measures, DGM showed the fastest annual 
rate of atrophy, which was faster in SPMS (-1.45%), PPMS (-1.66%), and RRMS (-1.34%) 
than CIS (-0.88%) and HCs (-0.94%)[p<0.01]. The rate of temporal GM atrophy in SPMS (-
1.21%) was significantly faster than RRMS (-0.76%), CIS (-0.75%), and HCs (-0.51%). 
Similarly, the rate of parietal GM atrophy in SPMS (-1.24-%) was faster than CIS (-0.63%) 
and HCs (-0.23%) (all p values <0.05). Only the atrophy rate in DGM in patients was 
significantly associated with disability accumulation (beta=0.04, p<0.001). 
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Interpretation: This large multi-centre and longitudinal study shows that DGM volume loss 
drives disability accumulation in MS, and that temporal cortical GM shows accelerated 
atrophy in SPMS than RRMS. The difference in regional GM atrophy development between 
phenotypes needs to be taken into account when evaluating treatment effect of therapeutic 
interventions. 
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Introduction 
The clinical course of multiple sclerosis (MS) is heterogeneous. Some patients experience 
relapses with recovery (relapsing-remitting [RR] MS), while others develop progressive 
disability either from the onset (primary-progressive [PP] MS), or after a period of relapses 
(secondary-progressive [SP] MS). RRMS patients account for approximately 90% of cases at 
onset1, whose majority later progress to SPMS. The pathogenic mechanisms driving accrual 
of disability are beginning to be elucidated2: neurodegeneration plays a crucial role in 
determining accrual of disability over time3. 
 
Neurodegeneration is reflected in-vivo by reduced brain volume (or brain atrophy), which can 
be measured by MRI3. Over time, brain volume declines more rapidly in MS patients when 
compared with age-matched healthy controls (HCs)3–6. Across MS phenotypes, SPMS shows 
the fastest annual rate of brain atrophy, which is estimated to be 0.6% (compared to about 
0.2% in age-matched HCs)5. The role of brain atrophy in monitoring response to treatments 
in MS is evolving: whole brain atrophy has been recently used as primary outcome measure 
in Phase II clinical trials in SPMS7,8.  
 
Whole brain atrophy is mainly driven by neuroaxonal loss in the GM3. GM volume loss is 
associated with long-term disability9,10, and explains physical disability better than white 
matter9,11 and whole brain atrophy5. Some GM regions, such as the cingulate cortex and 
thalamus, are affected by volume loss more extensively than others12,13, and the extent of 
their volume loss correlates with disability13,14, and cognitive impairment15. Regional 
predilection for atrophy is not unique to MS; for example, hippocampal atrophy is more 
pronounced than the whole brain atrophy in the early phase of Alzheimer’s disease16. 
Although cross-sectional studies have previously shown patterns of regional atrophy in 
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different types of MS12,17, studies on longitudinal evolution of atrophy in different structures 
across MS phenotypes are scarce. 
 
The overarching goal of our study was to investigate whether there is a spatiotemporal 
pattern of GM atrophy that is associated with faster disability accumulation in MS. In a large 
multi-centre cohort, which included all MS phenotypes and HCs, we tested the following 
hypotheses: (i) some GM regions show faster atrophy rate than others and their rate may 
differ between MS phenotypes; (ii) smaller baseline volumes of brain structures, reflecting a 
more extensive neurodegeneration, predict disability accrual; (iii) the rate of regional volume 
loss is associated with the rate of disability accumulation.   
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Methods 
Participants 
In this retrospective study, we collected data from 7 European MS centres (MAGNIMS: 
www.magnims.eu)  from 1,424 participants who have been studied between 1996 and 2016; 
we included participants who fulfilled the following criteria: (1) a diagnosis of MS according 
to 2010 McDonald Criteria18 or a clinically isolated syndrome (CIS)19; (2) healthy controls 
(HCs) without history of neurological or psychiatric disorders; (3) at least two-MRI scans 
acquired with a minimal interval of 6 months with identical protocol, including high-
resolution T1-weighted MRI (allowing regional grey and white matter segmentation), and 
T2/Fluid Attenuated Inversion Recovery (FLAIR), sequences. Patients were scored on 
Expanded Disability Status Scale (EDSS)20. To increase the number of HCs scans, which 
were provided by 4 centres, we collected data from age-matched HCs from the Parkinson’s 
Progression Marker’s Initiative (http://www.ppmi-info.org/data).  
MRI scans were taken under consent obtained from each subject independently in each 
centre. The final protocol for this study was reviewed and approved by the European 
MAGNIMS collaboration for analysis of pseudo-anonymised scans.  
Image acquisition 
We included scans from 13 different MRI protocols; all centres except one provided 3D-T1 
weighted scans (Supplementary Table 1 and Supplementary Table 2 show the MRI 
protocols).  
 
Image analysis 
We performed image analysis as follows: 
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1) Bias field correction 
We used N4 bias field correction to correct for field inhomogeneity in T1-weighted scans 
using ANTs v2.1021.  
2) Lesion filling 
Lesion masks were manually delineated on PD/T2 images by different raters at each centre 
semi-automatically, except for 3 centres that used the same automatic lesion segmentation 
with LST toolbox (version 2.0.15) 22.We calculated linear transformation matrices to register 
T2/FLAIR with the T1-weighted scan using FSL-FLIRT v5.023. Then we applied these 
matrices to lesion masks to transfer them into the accompanying T1 subject-space. We used 
the FSL lesion filling method which uses a white matter mask calculated with FSL-FAST24 to 
fill T1 hypo-intensities within normal-appearing whiter matter, so to reduce segmentation 
errors, as previously done25–27. 
3) Symmetric within-subject registration 
To avoid asymmetric registration and interpolation of longitudinal scans (e.g., toward the 
baseline scan), we constructed an unbiased subject-specific template that has “equal distance” 
from each time point using FreeSurfer version 5.328–30. We linearly transformed T1-weighted 
images to this symmetric space with the unbiased transformation matrix for each time point 
and used cubic B-spline interpolation to reduce interpolation artefacts. We manually checked 
the alignment of scans in the symmetric space. 
4) Tissue segmentation 
Next, in the symmetric space, we segmented T1 scans into the GM, white matter and 
cerebrospinal fluid with the Geodesic Information Flow (GIF) software (part of NifySeg, 
http://cmictig.cs.ucl.ac.uk/niftyweb/program.php?p=GIF)31, and parcellated each hemisphere 
into regions of interest according to the Neuromorphometric atlas32. GIF uses an atlas 
propagation and label fusion strategy to calculate the voxel probabilities of GM, white matter 
and CSF31; this method has been previously used in MS and other neurodegenerative 
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disorders33,34. The template library had 95 MRI brain scans (HCs and patients with 
Alzheimer’s disease) with neuroanatomic labels (http://www.neuromorphometrics.com/). 
This atlas, which is similar to Mindboggle atlas, was developed to improve the consistency 
and clarity of Desikan-Killiany protocol32.  
To calculate brain masks and exclude segmentation errors outside of the brain we used 
STEPS (Similarity and Truth Estimation for Propagated Segmentations, 
http://cmictig.cs.ucl.ac.uk/niftyweb/program.php?p=BRAIN-STEPS) based on a template 
library of 682 hand-drawn brain masks35,36. These maps were applied to each time point 
separately. 
5) Regional volume calculation 
We visually assessed the segmentations to assure the quality for statistical analysis. To 
calculate regional volumes, we summed the probability of the segmented tissue voxels (GM 
or white matter) in each parcellated region and multiplied the sum with the voxel volume.  
We averaged values between left and right hemispheres. Next, we summarised the regional 
volumes according to Neuromorphometrics protocol by summing the volume of GM regions 
in the temporal, parietal, occipital, frontal lobes, cerebellum and deep GM (DGM) [thalamus, 
putamen, globus pallidus, caudate, and amygdala]. We also obtained the volume of the 
brainstem and of the cerebral white matter. 
Figure 1 shows the image analysis pipeline.  
 
<……. Figure 1 ……  > 
 
Statistical analysis 
Brain volumes at baseline and rates of volume changes over time 
To investigate baseline volumes (intercept) and rates (slopes) of volume change by subject 
group and region, we used linear mixed-effects models with the volume at a given time as the 
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response variable, and time and interactions with time as fixed-effect covariates37. This 
model estimates adjusted rate while allowing for nested correlation structures, such as time of 
visit within subject within scanner, by incorporating, in this example, subject and scanner 
random intercepts, and a random slope on time. The interaction terms with time (e.g., subject 
group X time), allows the estimation of rate differences across the interacting variable, in this 
example subject groups or clinical phenotypes. Including another interaction with time, such 
as gender X time, adjusts the rate for gender. In addition to time, the fixed-effect covariates 
were: scanner magnetic field, subject group, gender, age at baseline, total intracranial volume 
(sum of the volumes of GM, WM and CSF) at baseline; and the interactions of each of these 
with time. Disease duration was too highly correlated with age at baseline to give reliable 
estimation, and was omitted from the final models. To estimate the percentage changes per 
unit (year) increase in time, we log-transformed the volume38. We adjusted time to zero for 
those visits in which a patient converted from one phenotype to another (e.g., CIS to RRMS). 
We performed post-hoc analyses to identify specific GM regions within the cerebral lobes 
and among the DGM nuclei that showed significant differences between MS phenotypes, as 
well as the default-mode network regions39. 
To investigate whether there is an association between the rate of loss in specific regions and 
MS phenotypes, 3-way interactions were used, for example, clinical phenotype × region × 
time. We used R (version 3.2.2) and the NLME package40,41.  
For each model, we visually checked the heteroscedasticity (which is the unequal variance of 
a variable across the range of values of a second variable that predicts it) per group by 
plotting residuals against the fitted values.  
We corrected for multiple comparisons accounting for the number of all the tests performed 
with the false-discovery rate method. 
Effect of MRI protocols on imaging measures  
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To assess the effect of the MRI protocol on MRI measures (we took into account the 
protocols rather than the centres because some centres acquired more than one protocol with 
more than one scanner) we included it as a fixed-effect variable in a separate mixed-effect 
model, and calculated the average effect sizes for MRI protocols and MS phenotypes (i.e., 
disease effects) while fixing other variables. 
Assessing associations between brain tissue volumes and disability accrual 
For easier interpretation of clinical and imaging measures, we standardised volumes by 
subtracting the mean and dividing by the standard deviation (Z-score). We analysed CIS and 
relapse-onset patients together, because some patients had converted from CIS to RRMS, or 
from RRMS to SPMS. This allowed us to take advantage of a longer follow-up period. With 
similar mixed-effects models we investigated the following three questions: (1) Are the 
baseline volumes of the DGM, the temporal, frontal, parietal, occipital and cerebellar GM, 
brainstem, and white matter, and white matter lesion load associated with EDSS at baseline? 
(2) Are changes in all these regional volumes and white matter lesion load associated with 
EDSS changes over time? (3) Do baseline volumes of all these regions and white matter 
lesion at baseline predict time-to-EDSS progression (event=EDSS progression) during 
follow-up? The EDSS-progression event was defined as 1.5 increase in EDSS, if the baseline 
EDSS was 0; one-point increase if EDSS was less than or equal to 6; and 0.5 increase if 
EDSS was more than 642. We used a Cox-regression model to explore whether baseline 
volumes of these structures predicted time to event. We performed a post-hoc analysis using 
all GM regions to determine the most important predictors of time-to-EDSS-progression (as 
defined above) and confirm that the results of the DGM were not affected by the bias of 
merging a higher number of cortical regions into the main lobes. We performed FDR 
correction to adjust for multiple comparisons. 
Additional analyses: software reliability and effects of disease modifying treatments  
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We carried out additional analyses to assess the reliability of brain volumes estimated with 
GIF software, FSL-FIRST, and SPM12, and effects of treatments on atrophy measures. We 
also performed area under the curve (AUC) analysis to examine the prognostic accuracy of 
adjusted DGM volumes at individual level (see Supplemental Material).  
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Results 
The MRI scans of 1,417 subjects were analysed (scans of three subjects were excluded due to 
significant motion artefacts on visual inspection and four due to registration issues because of 
missing MRI header information); 1,214 patients (253 had CIS, 708 had RRMS, 128 had 
SPMS, and 125 had PPMS), and 203 were HCs. In total, we analysed 3,604 T1-weighted 
MRI. Average number of scans per subject was 2.54 (SD=1.04), with an average follow up of 
2.41years (SD=1.97) for patients, and 1.83 (SD=1.77) years for HCs (see Table 1 for follow-
up information per group). The total numbers of participants with 3 or more visits for each 
group were: 90 HCs, 48 CIS, 334 RRMS, 39 SPMS, and 58 PPMS. A total of 96 patients 
with CIS (38%) converted to RRMS, and 28 patients with RRMS (4%) converted to SPMS 
during the follow-up. 
There was a significant difference in gender ratio between groups (p<0.001, see Table 1 for 
gender ratios). Patients with progressive MS (SPMS and PPMS) had significantly greater 
disability than patients with RRMS and CIS (Mann-Whitney tests, p<0.001, see Table 1), 
and were older than RRMS (p<0.001, average difference=10.7 years), CIS (p<0.01, average 
difference=15.6 years) and HCs (p<0.01, average difference=10 years). Age was similar 
between patients with RRMS and HCs. Patients with CIS were younger than HCs (p<0.01, 
average difference=4.9 years). Patients with CIS had the lowest T2 lesion load, and patients 
with SPMS had the highest T2 lesion load. About half of patients with RRMS were on 
disease modifying treatments (see Table 1).  
<… … Table 1 … … > 
Brain atrophy at baseline in MS and rates of volume changes over time  
At baseline, all clinical phenotypes (CIS, RRMS, SPMS, and PPMS) had significantly 
smaller cortical GM and DGM volumes than HCs. SPMS showed the lowest cortical GM and 
DGM volumes, followed by PPMS, RRMS, CIS. All clinical phenotypes, but not CIS, had 
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significantly reduced whole brain and white matter volumes when compared to HCs (see 
Figure 2A). 
 
The fastest regional decline in tissue volume over time was seen in the DGM in all clinical 
phenotypes (PPMS: -1.66% per year, SPMS: -1.45%, RRMS: -1.34%, CIS: -0.88%, p<0.01) 
and in HCs (-0.94%). The rate of atrophy in the DGM was greater in RRMS, SPMS and 
PPMS than CIS and HCs (all p values <0.01) (Figure 2B and Supplementary Tables 3 and 
4), but did not differ between RRMS, SPMS and PPMS. The rate of volume loss in the DGM 
in all MS patients together was significantly higher than that in the cortical and cerebellar 
GM and brainstem (although the rate of volume loss over time in these areas was still 
significant) (all p values < 0.05).  
 
The volume loss of the whole cortical GM was faster in SPMS (-1.11% per year), PPMS (-
0.79%), RRMS (-0.67%), than HCs (-0.34%)(all p values <0.05). Among the cortical regions, 
the temporal lobe GM showed a faster volume loss in SPMS (-1.21%) than RRMS (-0.77%) 
and CIS (-0.75%) (all p values <0.05) (Figure 2B and Supplementary Tables 3 and 4). 
Similarly, the parietal GM showed a faster volume loss in SPMS (-1.24%) than CIS (-0.63%) 
(p<0.05) (Figure 2B and Supplementary Tables 3 and 4). No differences in rates of 
volume loss were seen in the frontal and occipital GM between clinical phenotypes. Overall, 
all the cortical GM regions, with the exception of the occipital cortex, showed a faster rate of 
atrophy in MS than HCs (Figure 2B and Supplementary Table 4). 
The white matter did not show a significant rate of volume loss in HCs or any of the clinical 
phenotypes. 
There was no heteroscedasticity in the plots of residuals against fitted values. 
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In the post-hoc analyses when looking at regions and clinical phenotypes we found that 
among the DGM nuclei, the putamen showed the fastest volume loss in PPMS (-2.6%). 
Within the temporal lobe GM, the fastest volume loss was seen in the temporal pole (-1.47%) 
and posterior insula in SPMS (-1.19%). When looking at the parietal lobe GM, the precuneus 
showed the fastest atrophy rates in SPMS (-1.28%) (Figure 2C). Whilst the fastest rate of 
atrophy was seen in DGM in SPMS, the temporal lobe GM showed the highest difference 
between SPMS and HCs (see Figure 2C).  
 
There was no significant effect of gender on rates of atrophy. There was no significant 
association between GM volumes and T2 (or FLAIR) lesion load. 
<… … Figure 2 … … > 
 
Regions showing the highest rate of loss 
When we compared the rate of volume loss across different regions in all patients (CIS, 
RRMS, SPMS, and PPMS) together, the fastest decline (or lowest slope) was seen in the 
DGM (Supplementary Tables 3 and 4). The rate of loss in the cortical GM regions was 
similar between lobes and to that of the cerebellum. The slowest rate of loss was seen in the 
brainstem.  
 
Spatiotemporal pattern of GM volume loss in clinical phenotypes 
Although SPMS showed the lowest baseline volumes of cortical GM and DGM, and the rate 
of the DGM volume loss was faster in SPMS, PPMS and RRMS than CIS and HCs, there 
was no significant association between the rate of loss in specific regions and clinical 
phenotypes, which suggests that all clinical phenotypes share a similar spatiotemporal pattern 
of GM loss.  
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Effect of MRI protocols on imaging measures 
The average effects of MS phenotypes on brain volumes at baseline were higher than the 
protocol effect on the brain volumes (protocol effects: whole brain = 4.3%, cortical GM 
=5.1%, DGM = 8.5%, disease effects: whole brain = 4.8%, cortical GM =5.2%, 
DGM=13.7%). The average effects of MS phenotypes were higher than the effects of 
protocol on the rates of atrophy of the cortical GM and DGM (protocol effects: cortical GM = 
0.14%, DGM = 0.21%, disease effects: cortical GM = 0.57%, DGM =0.53%), but not those 
of the whole brain (protocol effect = 0.51%, and disease effect = 0.38%). 
 
Association between EDSS and GM loss  
In all clinical phenotypes combined, lower DGM and cortical GM volumes at baseline were 
associated with higher disability, as measured by the EDSS (𝛽: DGM 𝛽=-0.71, p<0.0001; 
cortical GM (𝛽=-0.22, p<0.0001). Under the assumption of a linear relationship between 
EDSS and GM volume, this suggests that for every Z-score decrease in the DGM and cortical 
volume at baseline, the baseline EDSS increased on average by 0.7 and 0.22, respectively.  
There was a significant progression of EDSS in both relapse-onset and PPMS patients, which 
on average increased by 0.07 and 0.2 per year, respectively. When we examined associations 
between the rate of EDSS changes and rate of changes in the volumes of cortical GM regions, 
cerebellar GM and DGM over time, only the rate of loss in the DGM was associated with 
disability accumulation (𝛽=-0.04, 95% CI: -0.02, -0.06, p=0.006). Under the assumption of a 
linear relationship between EDSS and rate of GM volume loss over time, this suggests that 
every standard deviation (Z-score) loss in the rate of DGM volume corresponded to an annual 
EDSS gain of 0.04. 
 
The percentage of patients who had EDSS progression during follow-up (or who experienced 
the “event”) was 26%. When we looked at baseline predictors of disability accumulation, 
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without any longitudinal imaging measure in the model, only the DGM predicted future 
EDSS progression. The hazard ratio [95% CI, p-value] for time-to-EDSS progression was 
0.73 [95% CI 0.65, 0.82, p<0.0001], which suggests that for every standard deviation (Z-
score) decrease in the DGM volume at baseline the risk of presenting a shorter time to EDSS 
worsening during the follow-up increased by 27% [95% CI: 18-35%]. The hazard ratio 
remained similar when we analysed relapse-onset and PPMS patients separately (0.72 and 
0.73 respectively). Figure 3 illustrates the survival-curve for these analyses.  
<… … Figure 3 … … > 
In the post-hoc analyses, baseline thalamic volume had the highest predictive value of EDSS-
progression during follow-up in both PPMS and the relapse-onset groups, by increasing the 
risk to a shorter time to EDSS worsening of 37% in relapse-onset MS and 40% in PPMS 
(Figure 4B and C). In this analysis, the predictive value of the thalamus was followed by that 
of the hippocampus and angular gyrus in relapse-onset MS (Figure 4B), and by that of the 
putamen, posterior insula and temporal pole in PPMS (Figure 4C). 
  
<… … Figure 4 … … > 
There were no significant differences in the rates of loss in patients who were receiving 
disease-modifying drugs and those who were not (see Supplementary Text). The analyses 
with GIF software, FSL-FIRST, and SPM12 confirmed the reliability of brain volumes 
estimates (see details in Supplementary Text). AUC analysis showed that DGM volumes 
were similar to a random classifier in prognosticating individual patients (see details in 
Supplementary Text).  
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Discussion 
In this large multicentre study, we have shown that volume loss in DGM over time was faster 
than that seen in other brain regions across all clinical phenotypes, and DGM volume loss 
was the only GM region associated with disability accumulation. Additionally, we found that 
the smaller DGM volume at baseline was associated with increased risk of shorter time to 
EDSS progression, in agreement with previous studies that showed smaller DGM volume 
associated with higher disability14,15. Interestingly, we found that atrophy rates of the GM of 
cortical lobes were the fastest in SPMS, and were faster in the temporal lobe in SPMS in 
comparison with RRMS and CIS and in the parietal lobe in SPMS in comparison with CIS. 
However, no significant association between cortical regions and disability progression was 
detected. Overall, our findings suggest that the development of DGM atrophy may drive 
disability accumulation irrespective of clinical phenotypes, thereby becoming a useful 
outcome measure in neuroprotective clinical trials. Although the spatiotemporal pattern of 
atrophy remains similar across MS phenotypes, some cortical regions show accelerated 
atrophy in SPMS than RRMS and/or CIS. We now discuss these results in turn and in detail. 
 
The pathological events that underpin DGM atrophy are not known, but this is generally 
interpreted as the result of neurodegeneration. Previous studies have shown that DGM 
atrophy is more severe in patients with progressive MS, longer disease duration and worse 
cognitive performance 14,15,43. Our post-hoc analyses showed that the thalamus, which is the 
DGM’s largest component, was a better predictor of future disability than other regions, and 
the rate of atrophy in the putamen was the highest across DGM nuclei. Previous studies, 
including those using advanced MRI, have found that thalamic damage at study entry was 
associated with higher disability13–15. DGM structures are extensively connected with cortical 
GM regions, and therefore DGM atrophy could be due to retrograde and anterograde 
neurodegeneration via tracts that connect GM areas. For example, the extent of cellular 
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density loss in the thalamus, is associated with neurodegeneration in the remote (but 
connected) cortical regions, over and beyond the extent of atrophy explained by 
demyelination in connecting tracts44. There is also evidence of other neurodegenerative 
mechanisms in the DGM nuclei. For example, their higher load of iron than other regions can 
accumulate oxidised lipids which are associated with neurodegeneration45. In our healthy 
controls, the rate of DGM atrophy was faster than that in other regions, suggesting that it may 
be a hot spot for both age- and disease-related atrophy in the human brain, although a 
methodological issue, related to its more uniform structure than other brain regions, cannot be 
excluded. In AUC analysis we found that at the individual level, DGM volume lacks 
prognostic value, which is due to the high variability typical of volumetric MRI studies46. 
Nevertheless, the DGM volume holds strong promise as a marker of disease progression (at 
the group level) with the potential to respond to neuroprotective treatments that target 
neurodegeneration in MS.  
Interestingly, the temporal lobe showed a significant acceleration in SPMS when compared to 
both RRMS and CIS. Similarly, the parietal lobe GM showed a significant acceleration of 
atrophy in SPMS in comparison with CIS. Our post-hoc analysis showed that the temporal 
pole and insula were the most affected structures in the temporal GM. Pathological studies 
have demonstrated an increase in the rate of neurodegeneration, especially in the temporal 
regions, during progressive stages of MS in comparison with RRMS and CIS47,48. Overall, a 
global pathological process in MS49, may become more pronounced in certain regions, such 
as the temporal GM, because of other mechanisms, such as static exposure to CSF (the insula 
in the temporal lobe) or hypoxia in watershed areas (some DGM nuclei such as the pallidum). 
For example, meningeal inflammation and cortical demyelination, which may play a role in 
cortical atrophy, preferentially affect deep sulci, such as the insula, where there is more 
exposure to static inflammatory cytokines2. Our findings also suggest that regions with more 
connections may be vulnerable to atrophy. For example, among the parietal cortical regions, 
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the precuneus, a core part of an important functional brain network (default mode network), 
showed the fastest atrophy rates in SPMS39. Thus, acceleration of atrophy during SPMS may 
be explained by cortical network collapse with advancing of degeneration from initial injury 
sites (focal lesions in the white matter or initial DGM degeneration) to interconnected 
neocortical systems50. We found that MS phenotypes shared a common spatiotemporal 
pattern of volume loss (no significant 3-way interaction of time × region × phenotype). 
This shows, in line with previous studies, that the difference in pathology of progressive MS 
is only quantitative rather than qualitative in comparison with RRMS2,51.  
 
Cortical GM atrophy was seen at study entry across clinical phenotypes, even in CIS, when 
compared with HCs, and was the greatest in progressive MS, in agreement with earlier 
studies17,52.Our findings of faster whole brain atrophy in SPMS, PPMS, RRMS than CIS, 
who in turn, showed higher cortical atrophy than HCs, are similar to previous studies on 
longitudinal whole brain atrophy5,53,54, regional atrophy17,55–57, and pathology of MS 
phenotypes2,47. Our study confirms our previous findings that relationships between whole 
brain atrophy and clinical changes are weak or absent5, and shows DGM atrophy as a 
stronger marker of clinical disability. Although the GM volumes of cortical lobes could not 
predict future EDSS progression, the more detailed post-hoc analyses showed that regional 
volumes, such those of the hippocampus and the angular gyrus, were associated with future 
EDSS progression. These regions are highly connected to other regions, and especially the 
angular gyrus (like the precuneus) acts as a hub in the default mode network, which could 
make it vulnerable to atrophy, as explained above39.  
 
This study was not designed to assess the effect of treatment on atrophy rates, but does study 
atrophy while adjusting for possible confounding effects. The rates of atrophy in all clinical 
phenotypes were similar in people who were receiving disease-modifying treatments to those 
 20 
who were not. Even though we could not ascertain the duration of treatments due to 
retrospective nature of this study, the majority (90%) of patients on disease modifying 
treatments, were receiving first-line injectable drugs (interferon or glatiramer acetate) before 
study entry. The effects of these drugs on brain atrophy are modest at best 58,59. Therefore, 
drug effects are unlikely to be confounders of our analysis. 
One strength of our study is that we included a large number of patients, who underwent the 
same protocol on the same MRI scanner over time at single sites. However, different MRI 
protocols could have an effect on atrophy measures and is a limitation of our study60,61. We 
therefore used a hierarchical statistical design based on scanner. Our study was powerful 
enough because the effects of clinical phenotype on the regional rates of atrophy were higher 
than the effects of between-centre variation.  
We chose GIF software to segment and parcellate the brain31 because it allowed inclusion of 
2D MRI data (which we had for one centre), and did not require any manual editing, unlike 
Freesurfer, which would have been unfeasible for such large number of scans. Our reliability 
analysis showed excellent agreement between GIF-derived DGM volume and that obtained 
using FSL-FIRST, and between GIF-derived cortical volumes and those obtained using 
SPM12, respectively. Therefore, we chose to present the results obtained with GIF because it 
allowed us to rely on only one method to segment DGM and cortical GM, and estimate TIV. 
We used TIV to adjust for variations in head size, rather than the skull-size, so that a more 
reliable estimate of head size is obtained, irrespectively of the field-of-view, the choice of the 
inferior cut-off of the brain for the analysis, and demographic factors (e.g., age, or weight)62. 
With regard to the statistical methods, we used mixed-effects models to calculate atrophy 
rates41, which naturally accommodated multiple (3 or more) time-points with varying 
intervals between follow-ups, and patients who convert from one phenotype to another (e.g., 
CIS to RRMS). These two issues are cumbersome to address with methods that rely on 
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pairwise comparisons (e.g., SIENA, BSI) and suffer from higher variance in brain atrophy 
estimates as the interval between two scans increases63,64. Mixed-effects modelling, instead, 
estimates a variance component to eliminate implausible inconsistencies65,66. Based on our 
experience and the results of this study, we recommend the acquisition of high-resolution 3D-
T1 images (isotropic 1mm3). Several methods can calculate DGM volumes, such as FSL-
FIRST, and GIF. We recommend the use of the GIF software when it is desirable to use the 
same method to segment both the cortex and DGM. 
There were also limitations in this study. The majority of centres did not provide MRI scans 
of HCs, however, we included a large number of HCs including those from an external 
initiative (PPMI). Our findings of volume changes in HCs were consistent with the literature. 
Meta-analyses have shown, in individuals less than 70 years of age, rate of whole brain loss 
ranges from 0 to -0.5 (our study = -0.04), GM loss ranges from 0 to -0.5% per year (cortical 
GM in our study = -0.34%)67, and the subcortical structures may show loss of up to -1.12% 
(DGM in our study = -0.94)68. Cognitive functions were not tested, and it is unknown 
whether cortical patterns of GM atrophy over time were associated with cognitive 
impairment. Clinical trials in MS (and in progressive MS in particular) include confirmed 
disability progression, based on the EDSS, as primary outcome measure. Although for EDSS 
the model-estimated coefficients and their p-values and confidence intervals are valid for 
comparison between brain regions, the absolute value of these coefficients must be 
interpreted with caution, because the EDSS does not have a uniform linear interpretation. 
Since this was a retrospective study, the duration of treatments before entry to the study could 
not be ascertained for all participants. Disease modifying drugs may have lasting effects, for 
example they may slow the accrual of disability after a decade59,69. Moreover, MRI sequences 
sensitive to cortical lesions were not available, and the effects of cortical lesions on atrophy 
measures remain unknown.  
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In conclusion, the DGM atrophy showed the most rapid development over time– extending 
previous cross-sectional studies that showed a relationship between DGM atrophy and 
disability– was most closely associated with disability accumulation and predicted the time to 
EDSS worsening. In phase II trials of neuroprotective medications in MS, DGM atrophy 
measures may therefore have greater potential to show treatment effects than other regional 
GM or whole brain measures. There was a disconnect between DGM atrophy and cortical 
atrophy rates. The temporal and parietal cortices showed a faster rate of atrophy in SPMS 
than RRMS and/or CIS, whilst DGM showed a faster rater of atrophy in SPMS than CIS 
only, suggesting that neurodegeneration in GM regions may proceed at a different rate which 
should be taken into account in the design of clinical trials. 
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Tables 
Table 1 Baseline characteristics of participants 
Group Healthy 
controls 
CIS RRMS SPMS PPMS 
Total number (number 
of females) 
203 (112) 253 (171) 708 (473) 128 (75) 125 (55) 
Average follow up in 
years (range) 
1.83 (0.5-7.8) 1.46 (0.5-13) 2.72 (0-13) 2.06 (0-5.5) 2.85 (0.5-6) 
Average age (± SD) 38.7 ± 10.5 33 ± 8 38.2 ± 9.8 48.2 ± 9.8 48.5 ± 10.1 
Average disease 
duration (± SD) 
— 0.4 ± 1.4 6.7 ± 7.3 15.6 ± 9.9 6.8 ± 5.9 
Median EDSS (range) — 
 
1 (0-4.5) 2 (0-7) 6 (2.5-9) 5 (2-8) 
Median T2 lesion load 
(ml) (1st-3rd quartiles) 
— 2.97  
(1.01-5.04) 
5.05  
(2.05-11.79) 
11.04  
(3.18-23.14) 
9.38 
(2.69-22.02) 
% (number) of patients 
on DMTs 
— 20%  
(52) 
49%  
(345) 
41%  
(52) 
6%  
(8) 
 
Table legend: Abbreviations: SD, standard deviation; CIS, clinically isolated syndrome; 
RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple 
sclerosis; PPMS, primary-progressive multiple sclerosis; ml, millilitre; EDSS, expanded-
disability status scale; DMTs: disease modifying treatment. 
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Figures Legends: 
Figure 1. Imaging analysis pipeline. An unbiased symmetric image registration approach 
was used to calculate atrophy.  
 
Figure 2. Baseline volumes, and annual percentage loss of brain regions in clinical 
phenotypes and healthy controls. Adjusted baseline values for HCs, CIS, RRMS, SPMS, 
and PPMS are shown in (A), where the adjusted mean is shown as a point, and error bars 
show the 95% confidence-interval. Adjusted P-values of pairwise comparisons between 
groups are shown in Supplementary Table 4. Longitudinal analyses are shown in (B) and (C). 
Bar charts of the adjusted annual percentage of loss are shown in (B) for the predefined 
regions. Height of each bar chart is the average estimate of the percentage annual loss from 
the mixed-effects model for each group. The error bars represent 95% confidence interval of 
these estimates. Adjusted P-values for pairwise comparison between regions across clinical 
phenotypes and HCs are shown in Supplementary Table 4. White matter volumes are not 
shown in (B, and C) because they did not show a significant change over time in any clinical 
phenotype. Post-hoc analyses of annual percentage loss are shown in (C) where DGM nuclei, 
temporal, limbic and default mode network regions were selected. Similar to (B) the adjusted 
average annual percentage volume loss for these regions is the height of each bar-chart and 
error bars represent 95% confidence intervals.  
Baseline values (A) and rates (B, and C) were adjusted in a single mixed-effects hierarchical 
model including age, gender, total intracranial volume at baseline, scanner magnetic field, 
and their interactions with time as the fixed-effects. Centre, subject and visits were nested 
(hierarchical) random-effects.  
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Abbreviations: HC, healthy controls; CIS, clinically isolated syndrome; RRMS, relapsing-
remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; PPMS, 
primary-progressive multiple sclerosis. 
 
Figure 3. DGM volume predicts future progression of EDSS. Survival curves for time to 
event (sustained EDSS progression, see methods for definition) in CIS, relapse-onset and 
PPMS. We have analysed CIS and relapse-onset patient together, because a proportion of 
patients convert from CIS to RRMS, or from RRMS to SPMS during the course of study. 
Hazard-ratios for models with continuous outcome variables (regional volumes) are reported.  
 
Figure 4. Risk of EDSS-progression during follow-up for each Z-score volume loss of 
the brain regions at baseline (post-hoc analysis). Results of the post-hoc Cox-Proportional 
Hazards univariate models are shown for the time-to-event analyses (event = sustained 
EDSS-worsening, see methods for the definition) in the regions of Neuromorphometrics’ 
atlas, which are shown in (A). The predictors were the baseline volumes of the regions shown 
in the x-axes of (B) for CIS, RRMS, and SPMS and (C) for PPMS. CIS, RRMS, and SPMS 
were analysed together, because several patients convert from one phenotype to another. 
Brain maps are shown in the left column, and bar-charts of the same analyses are shown in 
the right column of (B) and (C). Only regions whose P-value of the survival analysis 
survived FDR-correction (adjusted P<0.05) are shown in (B) and (C). The y-axes show the 
risk of progression for each Z-score loss in the volume of the corresponding brain region on 
x-axes. For example, for every Z-score loss of the thalamus volume at baseline, the risk of 
EDSS worsening during follow-up increased by 37% for the CIS, RRMS, SPMS group, and 
40% for PPMS. Colour maps code the importance of baseline volumes of the regions to 
predict EDSS-worsening (or EDSS-progression) during follow-up. The absolute values of 
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coefficients for ventricular volumes are shown in (B), because they have an effect in the 
opposite direction of other structures. Error-bars indicate the 95% confidence intervals. 
